1-4 of 4
Juan Jose Bargay
Close
Sort by
Journal Articles

GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years

Maria-Victoria Mateos, Bruno Paiva, Maria Teresa Cedena Romero, Noemi Puig, Anna Maria Sureda Balari, Albert Oriol, Enrique M Ocio, Laura Rosiñol, Yolanda González-Montes, Juan Jose Bargay, Esther Gonzalez Garcia, Miguel Teodoro Hernández Garcia, Angel Ramirez, Alexia Suarez-Cabrera, María-Jesús Blanchard, Sebastián Garzón, Luis Felipe Casado Montero, Valentin Cabanas Perianes, Jaime Pérez De Oteyza, Mercedes Gironella, Joaquin Martinez-Lopez, Ana-Isabel -Teruel, Pilar Delgado, Elena Prieto, Juan Jose Lahuerta Palacios, Joan Bladé, Jesus San Miguel
Journal: Blood
Blood (2023) 142 (Supplement 1): 209.
https://doi.org/10.1182/blood-2023-179866
Published: 2023
Journal Articles

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

Maria-Victoria Mateos, MD PhD, Enrique M. Ocio, MDPhD, Anna Sureda Balari, MD PhD, Albert Oriol, Esther González Garcia, MD, Maria José Moreno, Miquel Granell, MD, Fernando Escalante, MD, Veronica Gonzalez De La Calle, MD PhD, Laura Rosinol Dachs, Estrella Carrillo-Cruz, MD, Joaquín Martínez-López, Maria Victoria Dourdil Sahun, Marta Sonia Gonzalez, MD, Jaime Perez De Oteyza, MDPhD, Felipe De Arriba, PhD, Miguel T Hernández, MD PhD, Aránzazu García Mateo, PhD, Ana Pilar Gonzalez, PhD, Rafael Rios, MD PhD, Carmen Cabrera, Juan Jose Bargay, Paula Rodriguez-Otero, MD, Felipe Casado, Maria Casanova, MD, María Jesús Blanchard, Joan Blade Creixenti, Juan Jose Lahuerta, MD PhD, Jesus F. San-Miguel, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-140934
Published: 2020
Journal Articles

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Claire Burney, MBBS, Stephen Robinson, MBBS, PhD BSc, Ariane Boumendil, PhD, Hervé Finel, Irma Khvedelidze, Hannah Hunter, MB,FRCPath,MRCP, Xavier Poire, Bruno Lioure, MD, Karl S Peggs, Robin Foà, MD, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Tom Van Meerten, MD PhD, Juan Jose Bargay, Christoph Schmid, MD, Vergote Vibeke, Arnold Ganser, MD, Luca Castagna, MD, Ghulam J. Mufti, Silvia Montoto, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 701.
https://doi.org/10.1182/blood-2019-123442
Published: 2019
Journal Articles

Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hibridization (FISH)

Maria-Victoria Mateos, Norma C Gutierrez, María-Luisa Martín, Joaquín Martínez-López, MD PhD, Miguel T Hernandez, Rafael Martinez, MDPhD, Laura Rosiñol, MDPhD, Enrique M. Ocio, MD PhD, Ana Isabel Teruel, MD, Albert Oriol, MDPhD, Juan Jose Bargay, Enrique Bengoechea, Yolanda Gonzalez, MD, Jaime Perez De Oteyza, Mercedes Gironella, Cristina Encinas, Jesus Martin, Carmen Cabrera, Bruno Paiva, PhD, Noemi Puig, MD PhD, Joan Blade, MDPhD, Juan José Lahuerta, Jesus San Miguel, MDPhD
Journal: Blood
Blood (2015) 126 (23): 4243.
https://doi.org/10.1182/blood.V126.23.4243.4243
Published: 2015